ANN ARBOR, Mich., Sept. 10 /PRNewswire/ -- QuatRx Pharmaceuticals Company, a
privately-held biopharmaceutical company, today announced positive efficacy
results from the second of two patient cohorts in the second pivotal Phase 3
study for Ophena(TM) (ospemifene tablets), the company's investigational
compound in development for the treatment of postmenopausal vulvovaginal
atrophy (VVA). This study, together with the recent completion of a long-term
safety study for Ophena(TM), marks the end of the company's comprehensive
Phase 3 efficacy and safety program for Ophena(TM) and positions QuatRx to
file a New Drug Application (NDA) with the U.S. Food and Drug Administration
(FDA) in early 2010.
